PARIS, March 15, 2012 /PRNewswire/ -- Marken is pleased to share its year-end data which validates that it holds a market-leading position in the shipment of in-bound biological samples to the major central laboratories and to Pharma directly. In the past 18 months, Marken collected shipments from over 49,000 clinical investigators in 159 countries around the world. An independent survey* conducted by a major consulting group, confirms that Marken has more than 60% of the specialty courier market in biological samples transportation, and a higher share of the cold chain segment of that same market. Marken also commissioned an in-depth market research study in 2011 with The Avoca Group. The Avoca Group interviewed over 100 individuals, including current clients, from 74 global pharmaceutical, CRO, laboratory, and sponsor companies who use supply chain services. In the survey, Marken achieved the top score when asked “Who do you consider a leader in clinical trial logistics?” The qualities attributed to Marken’s leading position were cost effectiveness, flexibility, on-time performance and customer service. Marken intends to conduct this survey annually as a means to monitor and improve its client service position.
(Logo: http://photos.prnewswire.com/prnh/20110930/NY78064LOGO )
With its recent expansion in India and continued growth in Asia, Marken continues to broaden its reach and existing outbound shipments for the pharmaceutical industry which will include: drug product shipments, patient kit shipments, active pharmaceutical ingredients (API) shipments and medical devices. To support the growing demand, Marken has accelerated its development of pharmaceutical service depots in Asia, Europe, North America and Latin America whilst ensuring that the stringent Quality and Performance criteria of the temperature controlled supply chain are met.
“We are pleased to share the 2011 results from our independent research. The growth in biologics and the increasing need for temperature controlled supply chain will encourage more of our clients to use Marken for their time and temperature sensitive shipments,” said Wes Wheeler, Marken’s CEO. “We are experts in worldwide collection of patient samples which is derived from the personal visits we make to 49,000 clinical investigators in 159 countries. We have leveraged this expertise to our growing outbound business as well and will continue to expand our reach with new locations and new distribution services in the life science industries.”
About Marken
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.
*Survey Study Funded by Marken
SOURCE Marken
